China Pharma Holdings Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2007
Revenue	7.01	8.1	9.64	10.87	10.92	Upgrade
Revenue Growth (YoY)	-13.48%	-15.95%	-11.27%	-0.53%	-11.41%	Upgrade
Cost of Revenue	7.29	8.6	9.29	8.91	9.44	Upgrade
Gross Profit	-0.28	-0.49	0.35	1.95	1.48	Upgrade
Selling, General & Admin	2.25	2.96	3.15	4.04	4.64	Upgrade
Research & Development	0.24	0.19	0.32	0.38	0.23	Upgrade
Other Operating Expenses	-0.02	-0.09	-0.26	0.12	17.02	Upgrade
Operating Expenses	2.47	3.06	3.21	4.53	21.89	Upgrade
Operating Income	-2.75	-3.55	-2.86	-2.58	-20.41	Upgrade
Interest Expense / Income	0.33	0.43	0.54	0.29	0.32	Upgrade
Other Expense / Income	-0.01	-0.01	-0	-0.01	-0.03	Upgrade
Pretax Income	-3.08	-3.97	-3.4	-2.87	-20.7	Upgrade
Net Income	-3.08	-3.97	-3.4	-2.87	-20.7	Upgrade
Shares Outstanding (Basic)	3	1	1	1	1	Upgrade
Shares Outstanding (Diluted)	3	1	1	1	1	Upgrade
Shares Change	221.82%	13.96%	5.74%	0.10%	-	Upgrade
EPS (Basic)	-0.91	-3.78	-3.70	-3.50	-24.00	Upgrade
EPS (Diluted)	-0.91	-3.78	-3.70	-3.50	-24.00	Upgrade
Free Cash Flow	-0.71	-0.81	-0.69	-0.91	0.47	Upgrade
Free Cash Flow Per Share	-0.21	-0.77	-0.75	-1.04	0.54	Upgrade
Gross Margin	-4.01%	-6.09%	3.62%	17.97%	13.57%	Upgrade
Operating Margin	-39.25%	-43.79%	-29.67%	-23.73%	-186.82%	Upgrade
Profit Margin	-43.91%	-49.02%	-35.26%	-26.38%	-189.51%	Upgrade
Free Cash Flow Margin	-10.14%	-10.01%	-7.13%	-8.37%	4.32%	Upgrade
EBITDA	0.01	-0.84	0.23	0.11	-17.45	Upgrade
EBITDA Margin	0.12%	-10.34%	2.39%	0.98%	-159.75%	Upgrade
Depreciation & Amortization	2.75	2.7	3.09	2.68	2.93	Upgrade
EBIT	-2.75	-3.54	-2.86	-2.57	-20.38	Upgrade
EBIT Margin	-39.15%	-43.66%	-29.64%	-23.67%	-186.57%	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).